Terazosin
- (RS ) -1 - ( 4-amino- 6 ,7- dimethoxyquinazoline -2-yl ) -4 - ( tetrahydro-furan- 2-carbonyl ) piperazine ( IUPAC)
- (±) -1 - (4- amino-6 ,7- dimethoxyquinazoline -2-yl ) -4 - ( tetrahydro-furan- 2-carbonyl ) piperazine
- Rac -1-( 4-amino- 6 ,7- dimethoxyquinazoline -2-yl ) -4 - ( tetrahydro-furan- 2-carbonyl ) piperazine
- Terazosinum (Latin )
- C19H25N5O4
- C19H25N5O4 · HCl (hydrochloride)
- C19H25N5O4 · HCl · 2 H2O (hydrochloride dihydrate )
- 63590-64-7
- 63074-08-8 (hydrochloride)
- 70024-40-7 (hydrochloride dihydrate )
- G04CA03
- C02CA08
Antihypertensives
α1 -adrenoceptor antagonist
- 387.43 g.mol -1
- 459.92 g · mol -1 (hydrochloride dihydrate )
- From 272.6 to 274 ° C
- 278-279 ° C ( hydrochloride)
- 271-274 ° C (hydrochloride - dihydrate)
7.1
Hydrochloride
Attention
- 277 mg · kg -1 ( LD50, Rat, male, iv, hydrochloride dihydrate)
- 293 mg · kg -1 ( LD50, rat, female. , Iv, hydrochloride dihydrate)
Template: Infobox chemical / molecular formula search available
Terazosin is a drug from the group of alpha blockers, used for the treatment of clinical symptoms and bladder dysfunction in benign prostatic hyperplasia (BPH ), and - is used for the treatment of arterial hypertension - as a reserve drug. Terazosin was founded in 1977 by Abbott (trade name Hytrin ®), patented and is available as a generic in the trade.
It belongs, together with doxazosin and prazosin indoramin to the derivatives, as opposed to prazosin, however, it has a higher bioavailability ( 90%) and a longer half -life ( 10-18 h).
About kompetivien antagonism at the postsynaptic α1 - adrenoceptor blocking the action of noradrenaline and thus acts sympatholytic. About the thereby increased binding of norepinephrine at the presynaptic α2 -adrenoceptors it comes in addition to an increased effect. The hereby achieved blood pressure reduction ( with reduction of pre-and afterload ) makes you look in the therapy of arterial hypertension advantage.